PRRT2 and breast carcinoma: Previous studies demonstrate that ONC201 is synergistic with standard drugs in several cancers, e.g., with taxanes in breast cancer [37] and non-small cell lung cancer [7], with DNA-PKC inhibitor Nu7026 in hepatocellular carcinoma [60], gemcitabine in pancreatic cancer [52], with several drugs for haematological cancers (such as cytarabine, 5-azacytidine, bortezomib) to name a few [61].